CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Instagram Outage Disrupts Thousands of U.S. Users 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
 - EconoTimes)
NEW ORLEANS, Aug. 11, 2017 -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until September 26, 2017 to file lead plaintiff applications in a securities class action lawsuit against Foundation Medicine, Inc. (NasdaqGS:FMI), if they purchased the Company’s shares between February 26, 2014 and November 3, 2015, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of Massachusetts.
Get Help
Foundation Medicine, Inc. investors should visit us for more information about their rights at https://www.claimsfiler.com/cases/view-foundation-medicine-inc-securities-litigation\ or call to speak to our claim center toll-free at (844) 367-9658.
About the Lawsuit
Foundation Medicine and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
The alleged false and misleading statements and omissions include, but are not limited to, that: (i) the likelihood that the Company would be approved for reimbursement of its tumor tests by Medicare; (ii) the Company’s progress in doing so; (iii) the Company’s robust 2015 financial guidance; (iv) the assumption of Medicare approval on which its 2015 guidance was based; and (iv) as a result of the foregoing, Foundation’s financial statements were materially false and misleading at all relevant times.
About ClaimsFiler
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. ClaimsFiler's team of experts monitor the securities class action landscape and cull information from a variety of sources to ensure comprehensive coverage across a broad range of financial instruments.
To learn more about ClaimsFiler, visit www.claimsfiler.com.
